An ongoing phase Ib trial (NCT04167540) is designed to evaluate the safety and potential clinical effect of MRI-guided intraputaminal delivery of AAV2-GDNF in two cohorts of patients with either early-stage or advanced PD, thus contributing with important knowledge on the therapeutic effect early in PD course. Here, GDNF is linked to Parkinson disease.